Key Points
- David Mountcastle, Privia Health's CFO, sold 23,887 shares on Dec. 12 at an average of $25.03 for about $597,892, cutting his ownership by 12.14% to 172,909 shares (≈$4.33M).
- PRVA opened at $23.81 and trades in a 52-week range of $18.77–$26.51, with a market cap of $2.93 billion and a high P/E of 183.17 (50-day SMA $24.44, 200-day SMA $22.81).
- Wall Street sentiment is positive with a consensus "Moderate Buy" (12 Buys, 3 Holds), an average target of $30.42, and multiple analysts recently raising price targets into the low $30s.
Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) Director Matthew Shawn Morris sold 13,647 shares of Privia Health Group stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $25.01, for a total transaction of $341,311.47. Following the completion of the transaction, the director directly owned 68,188 shares of the company's stock, valued at $1,705,381.88. This trade represents a 16.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Privia Health Group Trading Down 2.2%
PRVA stock opened at $23.81 on Wednesday. Privia Health Group, Inc. has a 12-month low of $18.77 and a 12-month high of $26.51. The stock's 50 day simple moving average is $24.44 and its 200 day simple moving average is $22.81. The stock has a market capitalization of $2.93 billion, a PE ratio of 183.17, a price-to-earnings-growth ratio of 4.20 and a beta of 0.83.
Privia Health Group (NASDAQ:PRVA - Get Free Report) last issued its earnings results on Tuesday, June 7th. The company reported $0.10 earnings per share for the quarter. The business had revenue of $213.61 million during the quarter. Privia Health Group had a return on equity of 2.52% and a net margin of 0.89%. On average, research analysts predict that Privia Health Group, Inc. will post 0.14 earnings per share for the current year.
Analyst Ratings Changes
A number of research analysts have weighed in on PRVA shares. Barclays increased their target price on Privia Health Group from $22.00 to $23.00 and gave the company an "equal weight" rating in a report on Monday, November 10th. Stephens reissued an "overweight" rating and issued a $32.00 price objective on shares of Privia Health Group in a report on Thursday, December 4th. Evercore ISI upped their target price on shares of Privia Health Group from $28.00 to $30.00 and gave the company an "outperform" rating in a report on Friday, November 7th. Citizens Jmp increased their price target on shares of Privia Health Group from $30.00 to $31.00 and gave the stock a "market outperform" rating in a research report on Friday, November 7th. Finally, Citigroup reissued an "outperform" rating on shares of Privia Health Group in a research report on Friday, August 29th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Privia Health Group presently has an average rating of "Moderate Buy" and a consensus target price of $30.42.
Check Out Our Latest Research Report on PRVA
Hedge Funds Weigh In On Privia Health Group
Several institutional investors have recently bought and sold shares of PRVA. Vanguard Group Inc. boosted its holdings in shares of Privia Health Group by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company's stock valued at $301,263,000 after purchasing an additional 607,447 shares during the last quarter. Durable Capital Partners LP increased its position in Privia Health Group by 1.8% in the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company's stock worth $291,123,000 after purchasing an additional 203,842 shares during the last quarter. State Street Corp grew its stake in shares of Privia Health Group by 1.5% in the 2nd quarter. State Street Corp now owns 4,171,069 shares of the company's stock worth $95,935,000 after buying an additional 61,853 shares in the last quarter. Van Berkom & Associates Inc. increased its holdings in shares of Privia Health Group by 30.1% in the 3rd quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company's stock worth $93,987,000 after buying an additional 873,344 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Privia Health Group by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,655,569 shares of the company's stock valued at $61,086,000 after acquiring an additional 158,521 shares during the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.
Privia Health Group Company Profile
(
Get Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
